The settlement, announced on Wednesday, resolves 93% of all Zantac cases in state courts against GlaxoSmithKline.
In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a ...
GlaxoSmithKline Pharma is shifting focus to specialty treatments and preventive healthcare, emphasizing adult vaccines and ...
In a report released today, Rajan Sharma from Goldman Sachs maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a ...
London: Pfizer recently achieved a significant legal victory by winning bid in a London court to invalidate two patents held ...
GlaxoSmithKline Pharma, celebrating 100 years in India, is shifting to a specialty-focused model by entering the oncology ...
Malay Mail on MSN6d
GSK’s Arexvy vaccine approved to protect older adults from respiratory syncytial virus (RSV) disease in MalaysiaGlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced that Arexvy has been approved in Malaysia for respiratory ...
The concerns surrounding Zantac also prompted UK health authorities to advise doctors in 2019 to cease prescribing specific formulations of the drug as a precautionary measure. Reports indicated that ...
2don MSN
Mumbai: A retired GlaxoSmithKline (GSK) employee, Ashok Shetty, on Monday reported a home burglary involving the theft of ...
GlaxoSmithKline Pharmaceuticals Ltd. key Products/Revenue ... As on 30-06-2024, the company has a total of 16.94 Crore shares outstanding.As of 8th Oct,2024, the GSK Pharma Share Price on NSE closed ...
Teva Pharmaceutical Industries Ltd. ADR-0.76% $19.75B ...
GlaxoSmithKline is investing in artificial ... clients in one quarter of the time normally needed. Exscientia and GSK aim to discover novel and selective small molecules for up to 10 disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback